UCLA study finds deleting gene FLI1 boosts NK cell survival and slows solid tumors
Feb 22nd 2026
Using CRISPR to remove the gene FLI1 in human Natural Killer cells, researchers prevented nutrient-driven protein aggregate buildup that disables NK cells and showed improved tumor control in lab models, according to a study published in Immunity.
- Researchers identified FLI1 as a genetic brake that limits NK cell activity inside solid tumors.
- CRISPR deletion of FLI1 in human NK cells improved their survival and delayed solid tumor growth in experimental models.
- NK cells in solid tumor nutrient conditions accumulate protein aggregates that block activating signals and cause cell death.
- The team used tumor interstitial fluid medium from a mouse pancreatic cancer model, which may not exactly match the human tumor nutrient environment.
- The researchers have filed a provisional patent to edit FLI1 in human NK cells and are pursuing next-generation CRISPR strategies for clinical translation.
- The study appears in Immunity and was supported by the NIH and multiple research fellowships and foundations.